Beta Bionics Q3 sales up 63% YoY to $27.3M; raises full-year 2025 guidance

Beta Bionics, Inc.

2025-Q3 EPS reported -$1.52 revenue$68,130,000

Net sales $27.3M (+63% YoY); DME $21.0M (+45%), PBP $6.2M (+178%).
Gross margin 55.5% (+212 bps); net loss $14.2M vs $9.7M prior year.
Installed base 29,419 users (+162%); new patient starts 5,334 (+68%); 70% from MDI.
Adjusted EBITDA -$12.2M (negative 45% of sales); cash $274.0M.
Raised full-year 2025 guidance; specific numbers not disclosed in filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.